A Case of Hyperglycemic Hyperosmolar State Associated with Graves' Hyperthyroidism: A Case Report

INTRODUCTION

Thyroxine is one of counter-regulatory hormone in glucose homeostasis. Therefore, metabolic control in diabetes is negatively affected by thyrotoxicosis. Typically, hyperglycemic hyperosmolar state (HHS) occurs in elderly type 2 diabetes mellitus (DM). Thyrotoxicosis causes dramatic increase of glycogen degradation and/or gluconeogenesis and enhances breakdown of triglycerides. Thus, in general, it augments glucose intolerance in diabetic patients. A 23-yr-old female patient with Graves’ disease and type 2 DM, complying with methimazole and insulin injection, had symptoms of nausea, polyuria and generalized weakness. Her serum glucose and osmolarity were 32.7 mM/L and 321 mosm/kg, respectively. Thyroid function tests revealed that she had more aggravated hyperthyroid status; 0.01 mU/L TSH and 2.78 pM/L free T3 (reference range, 0.17-4.05, 0.31-0.62, respectively) than when she was discharged two weeks before (0.12 mU/L TSH and 1.41 pM/L free T3). Being diagnosed as HHS and refractory Graves’ hyperthyroidism, she was treated successfully with intravenous fluids, insulin and high doses of methimazole (90 mg daily). Here, we described the case of a woman with Graves’ disease and type 2 DM developing to HHS.

CASE REPORT

A 23-yr-old woman with type 2 DM and Graves’ disease has revisited to the Department of Emergency of Gyeongsang National University Hospital due to nausea, generalized weakness, polyuria and weight loss of 5 kg for 7 days in October 2003 since she was discharged from our hospital three weeks before. She was previously diagnosed as type 2 DM in 1996, and recently started insulin treatment to improve glycemic control due to persistently elevated HbA1c irrespective of oral administration of hypoglycemic agents. Three years before, she had taken propylthiouracil for hyperthyroid Graves’ disease for 2 yr. Being discharged two weeks before (0.12 mU/L TSH and 1.41 pM/L free T3). Being diagnosed as HHS and refractory Graves’ hyperthyroidism, she was treated successfully with intravenous fluids, insulin and high doses of methimazole (90 mg daily). Here, we described the case of a woman with Graves’ disease and type 2 DM developing to HHS.

Key Words : Hyperosmolar Hyperglycemic Nonketotic Coma; Graves Disease; Diabetes Mellitus, Type 2; Methimazole

Received : 11 April 2005
Accepted : 11 July 2005

Address for correspondence
Jong Ryeal Hahm, M.D.
Department of Internal Medicine, College of Medicine
Gyeongsang National University, 90 Chilam-dong,
Jinju 660-722, Korea
Tel : +82.55-759-0736, Fax : +82.55-759-0122
E-mail : jrhahm@ghsp.gnu.ac.kr

*This work was supported in part by Korea Research Foundation grant (KRF-2004-005-E00063).
levels of blood glucose (32.7 mM/L) and fructosamine (396 mM/L) were elevated. Her serum electrolytes and blood gas parameters were as follows: sodium 144.1 mM/L, potassium 5.4 mM/L, chloride 102 mM/L, calcium 2.5 mM/L, phosphorus 1.0 mM/L, pH 7.32, pCO2 35 mmHg, pO2 98 mmHg, and bicarbonate 16 mM/L. The fasting serum C-peptide was 0.44 mM/L. Serum anion gap was 20.9 and osmolality was calculated as 321 mosm/kg. Amylase and lipase levels were normal and anti-GAD antibody was negative. Thyroid function tests revealed that the patient had more aggravated hyperthyroid state; 0.01 mU/L TSH, 2.78 pM/L free T3 and 45.38 pM/L free T4 (RR, 11.41-23.08) than when she was hospitalized two weeks before (0.12 mU/L TSH, 1.41 pM/L free T3 and 30.26 pM/L free T4). TSH-receptor antibody level was 26.3 IU/L (RR, <1) and antimicrosomal antibody was 29.3 U/mL (RR, <60). The Tc-99m scan showed still enlarged thyroid with more increased uptake 6.5% than previous uptake scan (3.8%) performed taking propylthiouracil two months before. Based on above results, the patient was diagnosed as HHS accompanying mild ketosis on type 2 DM and aggravated Graves’ hyperthyroidism. We treated her with intravenous insulin injection and large volume of intravenous fluid administration. And also, she took high dose of methimazole (90 mg daily, six times a day) and beta-blockers. On the second day, nausea and generalized weakness have been improved.

At two months after acute presentation, we measured levels of C-peptide after 75 g glucose loading; 0 min (0.12 nM/L), 30 min (0.74 nM/L), 60 min (1.02 nM/L), 90 min (1.49 nM/L) and 120 min (1.32 nM/L). Throughout follow-ups for 2 months, she took insulin (0.9 units/kg/day), metformin (1,500 mg daily) and beta-blockers. On the second day, nausea and generalized weakness have been improved.

Two months after acute presentation, we measured levels of C-peptide after 75 g glucose loading; 0 min (0.12 nM/L), 30 min (0.74 nM/L), 60 min (1.02 nM/L), 90 min (1.49 nM/L) and 120 min (1.32 nM/L). Throughout follow-ups for 2 months, she took insulin (0.9 units/kg/day), metformin (1,500 mg daily) and beta-blockers. On the second day, nausea and generalized weakness have been improved.

At two months after acute presentation, we measured levels of C-peptide after 75 g glucose loading; 0 min (0.12 nM/L), 30 min (0.74 nM/L), 60 min (1.02 nM/L), 90 min (1.49 nM/L) and 120 min (1.32 nM/L). Throughout follow-ups for 2 months, she took insulin (0.9 units/kg/day), metformin (1,500 mg daily) and beta-blockers. On the second day, nausea and generalized weakness have been improved.

At two months after acute presentation, we measured levels of C-peptide after 75 g glucose loading; 0 min (0.12 nM/L), 30 min (0.74 nM/L), 60 min (1.02 nM/L), 90 min (1.49 nM/L) and 120 min (1.32 nM/L). Throughout follow-ups for 2 months, she took insulin (0.9 units/kg/day), metformin (1,500 mg daily) and beta-blockers. On the second day, nausea and generalized weakness have been improved.

Type 2 DM diagnosed Graves’ disease diagnosed First hospitalization HHS developed OPD visit after discharge

| PTU 300 mg/day | Methimazole 60 mg/day | Methimazole 90 mg/day | Methimazole 60 mg/day |
|----------------|-----------------------|-----------------------|-----------------------|
| Methimazole 60 mg/day | Methimazole 90 mg/day | Methimazole 60 mg/day |
| Lugol’s solution, Lithium Insulin 1.11 U/kg/day, 0.74 U/kg/day |

**DISCUSSION**

Thyrotoxicosis is accompanied by multiple metabolic abnormalities, with increased energy expenditure and excessive mobilization and utilization of metabolic substrates (6-8). Thyroid hormones enhance hepatic glucose output by increasing glucose metabolism such as gluconeogenesis and glycogenolysis (9-11). So, appropriate management in diabetic patients with hyperthyroidism is essential to control serum glucose level. In addition, excess of thyroid hormone triggers the breakdown of triglycerides stored in adipose tissue by enhancing lipid oxidation, resulting in increase of concentration and turnover of nonesterified fatty acids (9). Furthermore, hyperthyroidism augments renal clearance of insulin (13) and predisposes patients with thyrotoxicosis to lead to severe hyperglycemia and ketosis prone state. Therefore, these patients need more insulin...
administration.

The patient in this case shows 32.7 mM/L serum glucose, 321 mosm/kg osmolarity, arterial blood pH 7.32, and weak positive serum ketone on admission, suggesting that she has HHS and mild ketosis. She was also in more aggravated thyrotoxic state on admission than when she was hospitalized. Taking consideration of her good compliance to medication, thyrotoxicosis refractory to treatments with high dose of methimazole, and absence of any remarkable precipitating factors such as severe stressful conditions, systemic infection, major trauma, or myocardial infarction, and diseases or states elevated counter-regulatory hormones, we concluded that uncontrolled thyrotoxicosis might be a sole cause of her HHS development. Although we can not give a clear explanation for the mechanism why her Graves’ hyperthyroidism aggravated and became resistant to high dose of antithyroid drug, we, here, suggest several possible mechanisms. First, drugs administered for thyrotoxicosis during first hospitalization might facilitate the resistance of her thyroid tissue to methimazole. For example, Lugol’s solution are known to induce thyrotoxicosis by overriding the Wolff-Chaikoff effect in patients with nodular goiter (14). However, taking into account that Tc-99m scan showed much higher uptake on HHS development compared to first hospitalization (Fig. 1), this possibility looks very low. It has been reported that thyrotoxicosis also occurs in patients receiving long-term lithium carbonate for manic-depressive illness by immunogenetic mechanisms in prevalence of 0.7% (15). The possibility, though, is also not much regarding short duration of lithium exposure and promptness of onset of more serious thyrotoxicosis, we could not rule out that lithium carbonate might aggravate thyrotoxicosis by intensifying underlying autoimmune mechanisms. Another possibility is association of adrenergic receptor activation. For example, stress like HHS or ketosis induces activation of sympathetic nerves innervating the thyroid gland, and secretion of catecholamines which, in turn, might stimulate the synthesis of thyroid hormone (16). The elevated thyroid hormones then cause increase of the density of beta-adrenergic receptors, thereby enhances the effect of catecholamines. Lastly, though she stated that she had been in compliance with administration of antithyroid drug, we can not entirely rule out the possibility of irregular adherence.

In conclusion, HHS, a major acute complication of type 2 DM, can lead to serious consequences in patient with Graves’ hyperthyroidism if not managed promptly and effectively. Although HHS is rarely associated with Graves’ hyperthyroidism, here we confirm this unusual relation between HHS and thyrotoxicosis in a type 2 diabetic woman who undergone treatment with high dose of methimazole, Lugol’s solution and lithium carbonate for refractory hyperthyroid Graves’ disease.

REFERENCES

1. Alvin CP. Diabetes mellitus. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, Isselbacher KJ. Eds. Harrison’s Principles of Internal Medicine. 16th ed. McGraw-Hill 2004; 2152-80.
2. Bhattacharyya A, Wiles PG. Diabetic ketoadiposis precipitated by thyrotoxicosis. Postgrad Med J 1999; 75: 291-2.
3. Sola E, Morillas C, Garzon S, Gomez-Balaguer M, Hernandez-Mijares A. Association between diabetic ketoadiposis and thyrotoxicosis. Acta Diabetol 2002; 39: 235-7.
4. Kunishige M, Sekimoto M, Komatsu M, Bando Y, Uehara M, Izumi K. Thyrotoxicosis masked by diabetic ketoadiposis: a fatal complication. Diabetes Care 2001; 24: 171.
5. Gomez-Balaguer M, Saurina J, Gilansz A, Alonso C. Non-ketoacidic hyperosmolar diabetic decompensation caused by hyperthyroidism. An infrequent fact. Med Clin (Barc) 1990; 94: 116-7.
6. Randin J, Tappy L, Sczażigga B, Iezleri E, Group F. Insulin sensitivity and exogenous insulin clearance in Graves’ disease. Measurement by the glucose clamp technique and indirect calorimetry. Diabetes 1986; 35: 157-81.
7. Morrison W, Gibson J, Jung R, Rennie M. Skeletal muscle and whole body protein turnover in thyroid disease. Eur J Clin Invest 1998; 18: 62-8.
8. Beighton M, Martin C, Lavilie M, Riol JP, Cohen R, Mornex R. Lipolytic and ketogenic fluxes in human hyperthyroidism. J Clin Endocrinol Metab 1991; 73: 42-9.
9. Loeb JN. Metabolic changes in thyrotoxicosis. In: Bramenman LE, Uiter RD, eds. Werner and Ingbar’s The thyroid. Philadelphia: Lippincott-Raven 1996; 687-93.
10. Foss MC, Paccola GM, Saad MJ, Pimenta WP, Piccinato CE, Iazigi N. Peripheral glucose metabolism in human hyperthyroidism. J Clin Endocrinol Metab 1993; 70: 1167-72.
11. Utiger RD. The thyroid: physiology, thyrotoxicosis, hypothyroidism, and the painful thyroid. In: Felig P, Baxter JD, Frohman LA, eds. Endocrinology and metabolism. New York: McGraw-Hill 1995; 435-519.
12. Hagenfeldt L, Wernlund A, Felig P, Wahrend. J. Turnover and splanchnic metabolism of free fatty acids in hyperthyroid patients. J Clin Invest 1981; 67: 1672-7.
13. Nijs HG, Raader JK, Foolish M, Krams HM. Increased insulin action and clearance in hyperthyroid newly diagnosed IDDM patient. Restoration to normal with antithyroid treatment. Diabetes Care 1989; 12: 319-24.
14. Wilson R, McKillop JH, Crocket GT, Pearson C, Jenkins C, Burns F, Burnett AK, Thopson JA. The effects of lithium therapy on parameters thought to be involved in the development of autoimmune thyroid disease. Clin Endocrinol (Oxf) 1991; 34: 357-61.
15. Fradkin JE, Wolff J. Iodide-induced thyrotoxicosis. Medicine 1983; 62: 1-20.
16. Landsberg L. Catecholamines and hyperthyroidism. Clin Endocrinol Metab 1977; 6: 697-718.